| Host: |
E. coli |
| Reactivity: |
SARS-CoV |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-SARS-CoV Nucleocapsid-C-His protein was developed from e. coli and has a target region of C-His. For use in research applications. |
| Formulation: |
Supplied as a 0.22 Mu m filtered solution in 20mM TRIS, 500mM NaCl, 0.1mM EDTA, 20% Glycerol, pH8.0. |
| Endotoxin: |
Please contact us for more information. |
| Immunogen Region: |
Met1-Ala422 |
| Immunogen: |
Recombinant SARS-CoV Nucleocapsid Protein is produced by E. coli expression system. The target protein is expressed with sequence (Met1-Ala422) of sars-cov Nucleocapsid (Accession #NP_828858.1) fused with a 6×His tag at the C-terminus. |
| Background | Recombinant SARS-CoV Nucleocapsid Protein is produced by E. coli expression system. The target protein is expressed with sequence (Met1-Ala422) of sars-cov Nucleocapsid (Accession #NP_828858.1) fused with a 6×His tag at the C-terminus. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
